Premium
Retrospective analysis: Conservative treatment of placenta increta with methotrexate
Author(s) -
Zhang Chunhua,
Li Hongyan,
Zuo Changting,
Wang Xietong
Publication year - 2018
Publication title -
journal of obstetrics and gynaecology research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.597
H-Index - 50
eISSN - 1447-0756
pISSN - 1341-8076
DOI - 10.1111/jog.13590
Subject(s) - medicine , methotrexate , hysterectomy , curettage , retrospective cohort study , surgery , obstetrics , placenta , pregnancy , incidence (geometry) , conservative treatment , fetus , physics , biology , optics , genetics
Aim To evaluate the efficacy of conservative treatment with methotrexate against placenta increta by two different routes of administration through retrospective analysis. Methods A total of 54 women diagnosed with placenta increta after vaginal delivery were enrolled in this retrospective study. The participants accepted conservative management with methotrexate through either intravenous injection or local multi‐point injection under ultrasound guidance. The treatment was considered effective if no hysterectomy was mandatory during the follow‐up period. Results Out of the 54 cases, 21 patients were treated with methotrexate intravenously (group 1), and 33 patients received local multi‐point injection to the placenta increta under ultrasound guidance (group 2). No maternal death occurred. In group 1, 10 patients expelled the placentas spontaneously, 7 patients underwent uterine curettage and 4 patients underwent hysterectomy for uncontrollable post‐partum hemorrhage and infection. In group 2, 25 patients expelled placentas spontaneously and 8 patients underwent uterine curettage with no incidence of hysterectomy. The success rate in group 1 and group 2 was 17/21 and 33/33, respectively. The average time of the spontaneous placenta expulsion was 79.13 ± 29.87 days in group 1 and 42.42 ± 31.83 days in group 2. Conclusion Local multi‐point methotrexate injection under ultrasound guidance is a better alternative for patients with placenta increta, especially for preserving fertility.